Article

Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomide

2021-08-12

Abstract excerpt

Glioblastoma is the most fatal of all primary human brain tumors with 14 months survival, at best. The mainstay therapy for this tumor involves temozolomide, surgery, radiotherapy and tumor treating electric field. Cancer resistance to commonly available chemotherapeutics remains a major challenge in glioblastoma patients receiving treatment and unfavorably impact their overall survival and outcome. However, the l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4dde6551-773c-56b0-a30d-75e7bd06b446
DOI: 10.1101/2021.08.11.455972

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomideDOI 10.1101/2021.08.11.455972Read

Unlocking glioblastoma vulnerabilities with CRISPR-based genetic screeningSemantic proximity Read

Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic ScreeningSemantic proximity Read

Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR LibrariesSemantic proximity Read

Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.Semantic proximity Read

Integrated genetic screening reveals FEN1 as a driver of stemness and temozolomide resistance in glioblastomaSemantic proximity Read

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastomaSemantic proximity Read

Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapySemantic proximity Read

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read

Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysisSemantic proximity Read

Loss of CD99L2 contributed to temozolomide resistance and glioblastoma tumorigenesis based on Genome-scale CRISPR/Cas9 screeningSemantic proximity Read

Functional genomics to explore cancer cell vulnerabilities.Semantic proximity Read